Bladder-health diaries: An assessment of 3-day vs 7-day entries

BJU International

Volumn 96, Issue 7, 2005, Pages 1049-1054

  Dmochowski, Roger R ^a   Sanders, Steven W ^b   Appell, Rodney A ^c   Nitti, Victor W ^d   Davila, G Willy ^e  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Watson Pharmaceuticals Inc   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DEPARTMENT OF COLORECTAL SURGERY   (United States)

Author keywords

Bladder; Diaries; Overactive bladder; Oxybutynin; Urinary incontinence

Indexed keywords

DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MEMORY; MULTICENTER STUDY; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; STRESS INCONTINENCE; SUSTAINED RELEASE FORMULATION; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINE INCONTINENCE;

BENZHYDRYL COMPOUNDS; CHI-SQUARE DISTRIBUTION; CRESOLS; HUMANS; MANDELIC ACIDS; MEDICAL RECORDS; MUSCARINIC ANTAGONISTS; PATIENT COMPLIANCE; PHENYLPROPANOLAMINE; RANDOMIZED CONTROLLED TRIALS; SENSITIVITY AND SPECIFICITY; TIME; TREATMENT OUTCOME; URINARY BLADDER; URINARY INCONTINENCE;

EID: 27444439001     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05785.x     Document Type: Article

References (33)

1. Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78
2. Stewart WF, Van Rooyan JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36
3. National Center for Health Statistics. Fast Stats A to Z. Asthma, http://www.cdc.gov/nchs/fastats/asthma.htm Accessed July 2005
4. National Center for Health Statistics. Fast Stats A to Z. Diabetes, http://www.cdc.gov/nchs/fastats/diabetes.htm Centers for Disease Control and Prevention. Accessed July 2005
5. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003; 326: 841-4
6. Davila GW, Neimark M. The overactive bladder: prevalence and effects on quality of life. Clin Obstet Gynecol 2002; 45: 173-81
7. Dmochowski RR, Davila GW, Zinner NR et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002; 168: 580-6
8. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62: 237-42
9. Zinner N, Gittelman M, Harris R et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171: 2311-5
10. Novartis. Enablex® [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corp., 2004
11. GlaxoSmithKline. VESIcare® [package insert]. Research Triangle Park, North Carolina: GlaxoSmithKline, 2004
12. Erdem E, Akbay E, Doruk E, Cayan S, Acar D, Ulusoy E. How reliable are bladder perceptions during cystometry? Neurourol Urodyn 2004; 23: 306-10
13. Wagg A, Bayliss M, Ingham N, Arnold K, Malone-Lee J. Urodynamic variables cannot be used to classify the severity of detrusor instability. Br J Urol 1998; 82: 499-502
14. Appell RA, Sand P, Dmochowski R et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001; 76: 358-63
15. Dmochowski RR, Davila GW, Sanders SW. Transdermal oxybutynin and controlled-release oral tolterodine in patients with positive treatment effect to anticholinergic therapy for overactive bladder [abstract]. Neurourol Urodyn 2002; 21: 380
16. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine. a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001; 49: 700-5
17. Schick E, Jolivet-Tremblay M, Dupont C, Bertrand PE, Tessier J. Frequency-volume chart: the minimum number of days required to obtain reliable results. Neurourol Urodyn 2003; 22: 92-6
18. Lose G, Fantl JA, Victor A et al. Outcome measures for research in adult women with symptoms of lower urinary tract dysfunction. Neurourol Urodyn 1998; 17: 255-62
19. van Melick HH, Gisolf KW, Eckhardt MD, van Venrooij GE, Boon TA. One 24-hour frequency-volume chart in a woman with objective urinary motor urge incontinence is sufficient. Urology 2001; 58:188-92
20. Elser DM, Fantl JA, McClish DK. Comparison of 'subjective' and 'objective' measures of severity of urinary incontinence in women. Program for Women Research Group. Neurourol Urodyn 1995; 14: 311-6
21. McDowell BJ, Burgio KL, Dombrowski M, Locher JL, Rodriguez E. An interdisciplinary approach to the assessment and behavioral treatment of urinary incontinence in geriatric outpatients. J Am Geriatr Soc 1992; 40: 370-4
22. Diokno A, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78: 687-95
23. Gleason DM, Susset J, White C, Munoz DR, Sand PK. Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Urology 1999; 54:420-3
24. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50 (Suppl. 6A): 90-9
25. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57: 414-21
26. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45: 420-9
27. Chappie CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-10
28. Wyman JF, Choi SC, Harkins SW, Wilson MS, Fantl JA. The urinary diary in evaluation of incontinent women: a test-retest analysis. Obstet Gynecol 1988; 71: 812-7
29. Sommer P, Bauer T, Nielsen KK et al. Voiding patterns and prevalence of incontinence in women. A questionnaire survey. Br J Urol 1990; 66: 12-5
30. Larsson G, Victor A. Micturition patterns in a healthy female population, studied with a frequency/volume chart. Scand J Urol Nephrol Suppl 1988; 114: 53-7
31. Brown JS, McNaughton KS. Wyman JF et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology 2003; 61: 802-9
32. Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000; 48: 370-4
33. Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient non-compliance with paper diaries. BMJ 2002; 324: 1193-4